Hematologic Malignancy Clinical Trials

35 studies are recruiting for hematologic malignancy in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

   This study is a single-center, non-randomized, single-arm pilot trial of omidubicel hematopoietic stem cell transplantation (HCT) for hematologic malignancies with myeloablative conditioning chemotherapy of physician's choice followed by abatacept/tacrolimus/mycophenolate mofetil (ABA/Tac/MMF) graf…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Duke University Health System, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT06731504 on ClinicalTrials.gov

2. Diet and Cognitive Training in Hematologic Cancer Survivors

   The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer are: * is it feasible to combine a ketogenic diet supplementation and online cognitive training in an intervention program * will patients us…

   Stage

   Not phased

   Ages

   21 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05708716 on ClinicalTrials.gov

3. Immune Profiling for Cancer Immunotherapy Response

   In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

   Run by

   Dartmouth-Hitchcock Medical Center

   See if you can join NCT06116032 on ClinicalTrials.gov

4. Home Blood Transfusions

   This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Parti…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07121140 on ClinicalTrials.gov

5. BMT-CARE: Psychosocial Intervention for Transplant Caregivers

   The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and to identify critical facilitators and barriers for BMT-CARE implement…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Brimingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT06472089 on ClinicalTrials.gov

6. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov

7. HEME Home Transfusion Program

   This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancie…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06487247 on ClinicalTrials.gov

8. Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

   The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   5 in total

   Run by

   Tr1X, Inc.

   See if you can join NCT06462365 on ClinicalTrials.gov

9. αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)

   This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematop…

   Stage

   Not phased

   Ages

   Up to 30

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06082947 on ClinicalTrials.gov

10. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

    Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

    Stage

    Phase 1

    Ages

    1 to 21

    Site

    Children's Hospital Los Angeles, Los Angeles, California

    Locations

    31 in total

    Run by

    Therapeutic Advances in Childhood Leukemia Consortium

    See if you can join NCT05476770 on ClinicalTrials.gov